Outpatient removal of low-grade noninvasive bladder tumor with laser as good as TUR in GA, study says

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-09 14:30 GMT   |   Update On 2022-09-10 09:11 GMT

Denmark: Outpatient tumor removal with laser is as good as transurethral resection in general anesthesia and less burdensome to patients for the removal of recurrent low-grade Ta bladder tumor (BT), claims a recent study in European Urology.The study further showed that patients who underwent laser photocoagulation of bladder tumors (PC-BT) experienced a better postoperative quality of life,...

Login or Register to read the full article

Denmark: Outpatient tumor removal with laser is as good as transurethral resection in general anesthesia and less burdensome to patients for the removal of recurrent low-grade Ta bladder tumor (BT), claims a recent study in European Urology.

The study further showed that patients who underwent laser photocoagulation of bladder tumors (PC-BT) experienced a better postoperative quality of life, and the frequency of minor complications was lower.

Transurethral resection (TUR) of recurrent low-grade intermediate-risk Ta bladder tumor (BT) is burdensome to patients and the health care system in general anesthesia (GA). In office-based settings, laser technologies enable treatment, reducing morbidity and costs. Considering this, Gyrithe Lynghøj Pedersen, Department of Urology, Herlev-Gentofte Hospital, Capital Region of Denmark, Denmark, and colleagues performed a prospective randomized noninferiority trial comparing 4-months recurrence-free survival following outpatient department (OPD) diode laser coagulation of bladder tumor in local anesthesia and gold standard transurethral resection of BT (TUR-BT) in general anesthesia in intermediate-risk Ta low-grade BT, and to evaluate treatment-related morbidity.

The trial was performed in the Capital Region of Denmark from 2016 to 2020. Patients with verified Ta low-grade BT recurrence were included. Randomization was done on 206 patients; 176 finished treatment and follow-up per protocol.

Comparisons were made between laser photocoagulation of bladder tumor (PC-BT) in OPD using a 980 nm diode laser and gold standard TUR-BT in GA. Both were performed with photodynamic diagnosis (PDD) guidance.

The researchers assessed four-month recurrence-free survival; the predefined inferiority criterion was set at 15%. Pain during PC-BT, postoperative complications, postoperative morbidity, and patient preference were the secondary outcomes.

The study's key findings were as follows:

· After PC-BT, four-month recurrence-free survival was 8% higher. The predefined noninferiority criterion was met.

· Pain score (1–10) during PC-BT was 2.4.

· In the transurethral resection of the bladder group, the postoperative lower urinary tract symptom score (0–100) was 13.9 points higher.

· Following TUR-BT, the frequency of minor complications was 8.1% higher after TUR-BT.

· Of the patients, 98% preferred PC-BT.

"For the removal of recurrent low-grade Ta bladder tumors, PDD-guided PC-BT in OPD is as good as TUR-BT in GA," the researchers wrote. "After PC-BT, postoperative quality of life is better, and the frequency of minor complications was lower."

Reference:

Pedersen GL, Erikson MS, Mogensen K, Rosthøj S, Hermann GG. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol. 2022 Sep 1:S0302-2838(22)02564-7. doi: 10.1016/j.eururo.2022.08.012. Epub ahead of print. PMID: 36058804.

Tags:    
Article Source : European Urology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News